2025年12月17日,T-CURX宣布成功完成A轮首期2000万美元融资。本轮融资由欧洲与亚洲的投资者共同参与,所获资金将用于加速公司基于非病毒技术平台的CAR-T 疗法在急性髓系白血病(AML)及实体瘤领域的临床开发,并进一步推进其专有的in vivo CAR-T技术平台。本轮融资由BiomedVC领投,Bayern Kapital、HighLight Capital(弘晖基金)以及 i&...
Source Link2025年12月17日,T-CURX宣布成功完成A轮首期2000万美元融资。本轮融资由欧洲与亚洲的投资者共同参与,所获资金将用于加速公司基于非病毒技术平台的CAR-T 疗法在急性髓系白血病(AML)及实体瘤领域的临床开发,并进一步推进其专有的in vivo CAR-T技术平台。本轮融资由BiomedVC领投,Bayern Kapital、HighLight Capital(弘晖基金)以及 i&...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.